Latest Information Update: 07 Feb 2005
At a glance
- Originator TopoTarget UK
- Class Antipsoriatics
- Mechanism of Action Histone deacetylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 07 Feb 2005 Discontinued - Preclinical for Psoriasis in United Kingdom (Topical)
- 30 Oct 2002 Preclinical trials in Psoriasis in United Kingdom (unspecified route)
- 30 Oct 2002 PXD 103 is available for co-development opportunities [www.prolifix.co.uk]